ArticlePloS one2025
Integrated bulk RNA and single-cell analysis with experimental validation reveal oxidative stress-related diagnostic biomarkers for osteoporosis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Virus infections and cancers: from mechanisms to therapeutics.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis (OP) is a systemic skeletal disorder characterized by reduced bone mass and deterioration of bone microarchitecture, which increases fracture risk and impairs physical function. This study explores the role of CHRM2 in osteogenic differentiation and evaluates its potential as a biomarker for OP. Single-cell RNA sequencing revealed distinct differences in cell type distributions between OP patients and healthy controls, notably an increase in M1 macrophages and regulatory T cells in OP patients. Functional enrichment analysis underscored the involvement of regulatory T cells in OP pathogenesis. Furthermore, CHRM2 was identified as a key gene associated with oxidative stress. In vitro experiments demonstrated that CHRM2 knockdown enhanced osteogenic differentiation while suppressing cell proliferation, likely via interactions with COL4A2. These findings suggest that CHRM2 plays a negative regulatory role in osteogenic differentiation and may serve as both a diagnostic biomarker and a potential therapeutic target for early-stage OP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.